Teva launches generic drugs for HIV treatment

Teva launches generic drugs for HIV treatment

105
Teva launches generic drugs for HIV treatment

Teva launches generic drugs for HIV treatment

Teva Pharmaceuticals, announced the availability of the first Food and Drug Administration (FDA)-approved generic versions of TRUVADA and ATRIPLA tablets.

Brendan O’Grady, Executive Vice President, North America Commercial, Teva said, “These products, in addition to our more than 10 HIV-related medications already on the World Health Organization’s Essential Medicines list, represent Teva’s continued pursuit of treatments for HIV to improve health outcomes for the HIV community. During the COVID-19 pandemic, access to treatment is more essential than ever for those who are immunocompromised and at risk of developing more severe disease.”

These newly available generic medicines are indicated for:

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets:

Treatment of HIV-1 infection when used with other anti-HIV-1 medicines in adults and children who weigh at least 37 pounds (at least 17 kilograms)

HIV-1 pre-exposure prophylaxis (PrEP) to reduce the risk of getting HIV-1 infection in adults and adolescents who weigh at least 77 pounds (at least 35 kilograms)

Also read: Gujarat FDCA gears up for capacity enhancement of medical oxygen

Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets:

Treatment of HIV-1 infection in people who weigh at least 88 pounds (40 kilograms), alone as a complete regimen, or in combination with other anti-HIV-1 medicines

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets and Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are both combination treatments available as a single pill with similar safety profiles to their reference products.

Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are expected to be available through retailers and wholesalers at a Wholesale Acquisition Cost (WAC) of $48.51 per tablet. Efavirenz, Emtricitabine and Tenofovir Disoproxil Fumarate Tablets are expected to be available through retailers and wholesalers at a WAC of $78.86 per tablet.

The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.